LUCAR-G79 T cells

Phase 1Biologic

NNanjing Legend Biotech Co.

LUCAR-G79 T cells is one of 40 biologic programs targeting Autoimmune Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Blincyto

Amgen

Phase 2

1 5

Cytosar

Teva

Phase 2

1 6

Soliris

Rayos

2 8

Alkeran

AApotex Inc.

Phase 2

1 9

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

1 10

Vepesid

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

Autoimmune Disease

NCT07049081

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases

Recruiting·NNanjing Legend Biotech Co.·Phase 1·NCT07049081·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LUCAR-G79 T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LUCAR-G79 T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LUCAR-G79 T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing Legend Biotech Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNanjing Legend Biotech Co.

LUCAR-G79 T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Autoimmune Disease1 trial

References

Drug Info

Quick Facts

Related News